The center is now preparing to expand the drill to the rest of the country after performing a dry run of vaccination in Assam, Andhra Pradesh, Punjab, and Gujarat on December 28 and 29, so that once a vaccine dose is authorized for emergency use, the administration of the vaccine continues without a malfunction anywhere. In at least 3 session locations on January 2, all state capitals will perform dry runs. Municipalities that are located in rugged terrain or who have poor logistical support would often involve certain states.
The whole system of delivering vaccines from storage to the ground, administering them to candidates in the dry run of the vaccine, feeding data on the Co-WIN app is achieved without any actual vaccine. For instance, 475 beneficiaries underwent the dummy procedure in Gujarat dry run, the main purpose of which is to determine whether there is any weakness in the structured program. The mock drills even practice crowd control at a booth, maintaining social distancing rules within the booth.
Dry Run In Various Parts Of India:
In Gujarat, the dry run was performed at 19 booths set up in Gandhinagar and Rajkot districts. For the dry run, Ludhiana and Shaheed Bhagat Singh Nagar have been selected in Punjab. Nalbari and Sonitpur were the two Assam districts where the mock drill had already occurred. For the two-day drill, the Krishna district of Andhra Pradesh was picked. The practice went on effectively all over the place.
The proposal to expand the dry run to all states and Union territories comes in the midst of India’s apex drug regulator body, suggesting that India might begin the fresh year with a Covid-19 vaccination.
“We will have a Happy New Year with something in hand, that’s all I can hint at,” said VG Somani, Drug Controller General of India (DCGI), on Thursday.
The subject expert committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) will meet on January 1 to consider the emergency-use authorization for these vaccines. In India, the implementation of the vaccine is from three companies— Serum Institute of India (it is to manufacture the Oxford AstraZeneca vaccine), Pfizer, and Bharat Biotech’s Covaxin.
There is also a plan for the distribution of the vaccine which includes a hierarchical method for the task. In order to make things run smoothly, the government has decided to distribute the vaccine to doctors and front-line workers first and later to the common people.
